Table 3 Predictive power of multimarker panels
From: Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
Panel | Timepoint | Response type | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|
α-Fetoprotein, soluble vascular cell adhesion molecule 1, MMP-9 | Pretreatment | Clinical complete response versus no response | 83 | 91 |
Tissue plasminogen activator inhibitor 1 | Pretreatment | Clinical complete response/clinical partial response versus no response | 75 | 77 |
MMP-3, luteinizing hormone, thyroid-stimulating hormone | Pre-cycle 2 | Clinical complete response versus no response | 82 | 73 |
ErbB2, epidermal growth factor receptor, migration inhibitory factor, MMP-2, CD40 ligand | Pre-cycle 2 | Pathologic complete response/pathologic partial response versus no response | 85 | 69 |